Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
18
10
2021
accepted:
28
01
2022
revised:
14
01
2022
pubmed:
18
2
2022
medline:
6
4
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Primary liver cancer (PLC) comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) represents the third deadliest cancer worldwide with still insufficient treatment options. We have previously found that CD4 T helper 1 (Th1) response is indispensable for the protection against PLC. In the present research, we aimed to test the potent inducers of Th1 responses, live-attenuated Listeria monocytogenes ∆actA/∆inlB strain as preventive/therapeutic vaccine candidate in liver fibrosis, HCC, and CCA. Studies were performed using autochthonous models of HCC and CCA, highly reflecting human disease. L. monocytogenes ∆actA/∆inlB demonstrated strong safety/efficacy in premalignant and malignant liver diseases. The protective mechanism relied on the induction of strong tumor-specific immune responses that keep the development of hepatobiliary cancers under control. Combination therapy, comprising Listeria vaccination and a checkpoint inhibitor blockade significantly extended the survival of HCC-bearing mice even at the advanced stages of the disease. This is the first report on the safety and efficacy of Listeria-based vaccine in liver fibrosis, as well as the first proof of principle study on Listeria-based vaccines in CCA. Our study paves the way for the use of live-attenuated Listeria as safe and efficient vaccine and a potent inducer of protective immune responses in liver fibrosis and hepatobiliary malignancies.
Identifiants
pubmed: 35173308
doi: 10.1038/s41388-022-02222-z
pii: 10.1038/s41388-022-02222-z
pmc: PMC8853207
doi:
Substances chimiques
Cancer Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2039-2053Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cancer .
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol. 2020;72:209–14.
doi: 10.1016/j.jhep.2019.11.006
pubmed: 31954486
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28–v37.
doi: 10.1093/annonc/mdw324
pubmed: 27664259
Liver. EAftSot. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
doi: 10.1016/j.jhep.2018.03.019
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl J Med. 2008;359:378–90.
doi: 10.1056/NEJMoa0708857
pubmed: 18650514
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl J Med. 2020;382:1894–905.
doi: 10.1056/NEJMoa1915745
pubmed: 32402160
Ley C, Wedemeyer H. Das hepatozelluläre karzinom. Onkol Heute. 2019;11:51–8.
Lee HW, Cho KJ, Park JY. Current status and future direction of immunotherapy in hepatocellular carcinoma: what do the data suggest? Immune Netw. 2020;20:e11.
doi: 10.4110/in.2020.20.e11
pubmed: 32158599
pmcid: 7049588
Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931–52.
doi: 10.1080/21645515.2017.1359362
pubmed: 29112462
pmcid: 5718787
Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–51.
doi: 10.1038/nature10599
pubmed: 22080947
Yevsa T, Kang TW, Zender L. Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development. Oncoimmunology. 2012;1:398–9.
doi: 10.4161/onci.19128
pubmed: 22737629
pmcid: 3382854
Hoenicke L, Zender L. Immune surveillance of senescent cells–biological significance in cancer- and non-cancer pathologies. Carcinogenesis. 2012;33:1123–6.
doi: 10.1093/carcin/bgs124
pubmed: 22470164
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell. 2016;30:533–47.
doi: 10.1016/j.ccell.2016.09.003
pubmed: 27728804
pmcid: 7789819
Flickinger JC, Jr, Rodeck U, Snook AE. Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines. 2018;6:48.
Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA. 2004;101:13832–7.
doi: 10.1073/pnas.0406035101
pubmed: 15365184
pmcid: 518841
Crowther MD, Svane IM, Met O. T-cell gene therapy in cancer immunotherapy: why it is no longer just CARs on the road. Cells 2020;9:1588.
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649–59.
doi: 10.1016/S0092-8674(00)80452-3
pubmed: 9393858
Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, et al. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med. 2016;22:744–53.
doi: 10.1038/nm.4107
pubmed: 27213815
Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, Soung MC, et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 2002;62:2287–93.
pubmed: 11956085
Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol. 2009;182:5537–46.
doi: 10.4049/jimmunol.0803742
pubmed: 19380802
Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res. 1999;59:2217–22.
pubmed: 10232611
O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24:4436–47.
doi: 10.3748/wjg.v24.i39.4436
pubmed: 30357021
pmcid: 6196335
Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013:196704.
doi: 10.1155/2013/196704
pubmed: 23840211
pmcid: 3690205
Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci. 2009;54:2016–25.
doi: 10.1007/s10620-009-0867-4
pubmed: 19517231
Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138–46.
doi: 10.1038/nm.3679
pubmed: 25216638
pmcid: 4587571
Seehawer M, Heinzmann F, D’Artista L, Harbig J, Roux PF, Hoenicke L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562:69–75.
doi: 10.1038/s41586-018-0519-y
pubmed: 30209397
pmcid: 8111790
Petriv N, Neubert L, Vatashchuk M, Timrott K, Suo H, Hochnadel I, et al. Increase of alpha-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. Oncoimmunology. 2021;10:1874159.
doi: 10.1080/2162402X.2021.1874159
pubmed: 33628620
pmcid: 7889131
Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325–33.
doi: 10.1200/JCO.2014.57.4244
pubmed: 25584002
pmcid: 4397277
Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, et al. Results from a Phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019;25:5493–502.
doi: 10.1158/1078-0432.CCR-18-2992
pubmed: 31126960
pmcid: 7376746
Deng W, Lira V, Hudson TE, Lemmens EE, Hanson WG, Flores R, et al. Recombinant Listeria promotes tumor rejection by CD8(+) T cell-dependent remodeling of the tumor microenvironment. Proc Natl Acad Sci USA. 2018;115:8179–84.
doi: 10.1073/pnas.1801910115
pubmed: 30038013
pmcid: 6094133
Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, et al. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene. 2012;31:2140–52.
doi: 10.1038/onc.2011.395
pubmed: 21927025
Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol. 2014;11:184–96.
doi: 10.1038/cmi.2013.64
pubmed: 24488178
pmcid: 4003383
Zenewicz LA, Shen H. Innate and adaptive immune responses to Listeria monocytogenes: a short overview. Microbes Infect. 2007;9:1208–15.
doi: 10.1016/j.micinf.2007.05.008
pubmed: 17719259
pmcid: 2042024
Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, et al. Antigen specificity and clinical significance of IgG and IgA autoantibodies produced in situ by tumor-infiltrating B cells in breast cancer. Front Immunol. 2018;9:2660.
doi: 10.3389/fimmu.2018.02660
pubmed: 30515157
pmcid: 6255822
Wang J, Lin D, Peng H, Huang Y, Huang J, Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. Cell Death Dis. 2013;4:e945.
doi: 10.1038/cddis.2013.474
pubmed: 24309932
pmcid: 3877547
Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front Immunol. 2021;12:613530.
doi: 10.3389/fimmu.2021.613530
pubmed: 33841396
pmcid: 8024581
Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551:340–5.
doi: 10.1038/nature24302
pubmed: 29144460
pmcid: 5884449
Gu Y, Liu Y, Fu L, Zhai L, Zhu J, Han Y, et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat Med. 2019;25:312–22.
doi: 10.1038/s41591-018-0309-y
pubmed: 30643287
DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol. 2008;180:361–71.
doi: 10.4049/jimmunol.180.1.361
pubmed: 18097037
Luedde T, Schwabe RF. NF-kappaB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108–18.
doi: 10.1038/nrgastro.2010.213
pubmed: 21293511
pmcid: 3295539
Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccin Immunol. 2009;16:96–103.
doi: 10.1128/CVI.00274-08
Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauss A, et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280.
doi: 10.3389/fimmu.2020.01280
pubmed: 32849491
pmcid: 7426526
Xu G, Feng D, Yao Y, Li P, Sun H, Yang H, et al. Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. Oncogene. 2020;39:1429–44.
doi: 10.1038/s41388-019-1072-3
pubmed: 31659256
Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, et al. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. J Immunother Cancer. 2019;7:132.
doi: 10.1186/s40425-019-0601-5
pubmed: 31113479
pmcid: 6529991
Gilley RP, Dube PH. Checkpoint blockade inhibitors enhances the effectiveness of a Listeria monocytogenes-based melanoma vaccine. Oncotarget. 2020;11:740–54.
doi: 10.18632/oncotarget.27490
pubmed: 32133048
pmcid: 7041938
Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18:291–7.
doi: 10.1016/j.aohep.2019.04.003
pubmed: 31047849
Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.
doi: 10.1038/ng.3252
pubmed: 25822088
pmcid: 4587544